Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.
This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.
Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.
This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.
Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.
In addition, Zelda is building a pre-clinical research portfolio targeting cancer.
The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.
If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.
Zelda Therapeutics trade higher on medical cannabis focus
Published: 11:00 20 Mar 2017 AEDT